Our Mission

Established in 2013, the Oklahoma Clinical and Translational Science Institute serves as a catalyst for clinical and translational research that improves health and healthcare for Oklahomans, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Shared Clinical and Translational Resources

OSCTR is Oklahoma's NIH-funded IDeA-CTR that provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in the state

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

Oklahoma Shared Clinical and Translational Resources Community-Engaged Research Exploratory (CERE) Awards

This program is intended to support community engagement to develop funded research partnerships. Funds can be used for research development activities, including convening partners, working with individuals pursuing related work, and conducting needs assessments in community settings. The funds cannot be used to support actual human-subjects research protocols, which can be funded under other OSCTR pilot research programs and/or external funding.

Plasma Exosomes Show Promise for Early Detection of Pancreatic Cancer

Pancreatic cancer is the fourth leading cause of cancer deaths in the United States, and pancreatic cancer has some of the lowest 5-year survival rates of any cancer. Early detection can improve survival rates. When pancreatic ductal adenocarcinoma is initially diagnosed at stage IV, patients have a 2.7% 5-year survival rate. When diagnosis occurs at Stage I or IIA, this improves to 34%. However, there are currently no accurate blood tests for early detection of pancreatic cancer.

ECHO Grant Awarded to OUHC

The OCTSI has partnered with the OUHC Department of Pediatrics and been awarded a grant from the National Institutes of Health to develop the Oklahoma Pediatric Clinical Trial Network. This network will be part of the IDeA States Pediatric Clinical Trials Network that is participating in the Environmental Impacts of Child Health Outcomes (ECHO) Program to effectively investigate the impacts of environmental exposures from the womb through later years in a child’s life. The Principal Investigator of this award is Dr. Paul Darden, Chief of General and Community Pediatrics at OUHC.

Subscribe to News

Recent Publications

Surfactant proteins A and D nucleotide variants: association with retinal vascular disease

Pediatr Res. 2025 Oct 16:10.1038/s41390-025-04435-w. doi: 10.1038/s41390-025-04435-w. Online ahead of print.

ABSTRACT

BACKGROUND: Retinopathy of prematurity (ROP) is associated with systemic inflammation. Surfactant proteins A and D (SP-A and SP-D) play an immunomodulatory role. We previously reported the impact of SP-A on retinal angiogenesis. This study investigates SP-A and SP-D single-nucleotide polymorphisms (SNPs) with risk of ROP.

Quantifying the Drivers of Survival: A Matched Cohort Study of Trauma Center-Level Differences

J Surg Res. 2025 Oct 22;315:688-698. doi: 10.1016/j.jss.2025.09.071. Online ahead of print.

ABSTRACT

INTRODUCTION: Tertiary trauma centers (levels I and II) offer comprehensive care and are equipped to manage complex injuries. Trauma patients treated at tertiary centers have better survival outcomes. However, the specific interventions driving this advantage remain unknown. This study aimed to identify interventions contributing to differences in short-term mortality between tertiary trauma centers (TTCs) and nontertiary trauma centers (NTCs).

Upcoming Events

Media